Le Lézard
Classified in: Health
Subject: FDA

CryoConcepts Receives FDA Clearance on Two Cryosurgical Devices for the Physician Office Market


BETHLEHEM, Pa., May 8, 2019 /PRNewswire/ -- CryoConcepts, LP, a market leader in the development and manufacture of cryosurgical products, announced today they have received FDA clearance on two new, patent pending, cryosurgical devices for the physician's office market.   

CryoTouchtm  is a portable cryosurgical device that delivers cryogen to lesion sites and can use either applicators or cones based on the physician's preference. CryoLab® is a benchtop unit that delivers cryogen for medical practices that perform a high volume of cryosurgery. The new platforms have been cleared to treat up to 23 different indications.

"We are excited to get these clearances from the FDA," said Sam Niedbala, PhD and CEO of CryoConcepts, LP. "CryoTouchtm  and CryoLab® have been designed to address user needs in a product category that has not seen innovation in over two decades. Our new, patent pending, products will deliver greater efficacy and are much easier-to-use. These new products position CryoConcepts as the only company that is a one-stop source for cryosurgical products ranging from disposable devices to capital equipment," he added.

The largest portion of the professional cryosurgical market consists of two basic product categories ? 1. Liquid nitrogen-based delivery systems used mainly by dermatologists which require frequent refills due to evaporation and 2. Portable devices such as the Histofreezer® and Verrucae Freeze® that are disposable can-like devices used by Pediatricians and General Practitioners.

"Histofreezer® and Verrucae Freeze® established the disposable cryosurgical market in the early 90's," said Bill Hinchey, CMO of CryoConcepts. "Our new products are easy-to-use and deliver more effective treatments while being highly efficient," he added.

The company plans aggressive introductions into a variety of professional medical markets during 2019. CryoConcepts currently markets other cryo devices under the CryOmega®, CryoClear®, and CooLifting® brand names.

About CryoConcepts, LP

CryoConcepts was founded by Sam Niedbala, PhD, in 2009 and is located in Bethlehem, PA.  Dr. Niedbala was a co-founder and former Chief Science Officer of OraSure Technologies, Incorporated (NASDAQ: OSUR) and holds over 50 US and international patents. The management team also includes another OraSure co-founder, Bill Hinchey, who was responsible for the US launch of Histofreezer in 1991 and spent over a decade in the cryosurgical business. Mr. Hinchey serves as Chief Marketing Officer of CryoConcepts. P. Michael Formica is CryoConcepts' Chief Technology Officer and served as an Executive Vice President at OraSure Technologies from 2000 to 2016. Mr. Formica was General Manager of the domestic, international, and OTC Histofreezer business during his tenure at OraSure. 

For more information, please visit www.CryoConcepts.com.

SOURCE CryoConcepts, LP


These press releases may also interest you

at 02:52
A British study initiated by researchers in which endurance athletes used Enzymatica's ColdZyme®® cold spray shows significantly shorter duration of common colds and milder common cold symptoms compared with endurance athletes in the untreated group....

at 02:35
FSD Pharma Inc. (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201...

at 02:34
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) reports the best earnings year in its history, exceeding its three financial goals. Our success and growth are built on high levels of customer satisfaction,...

at 02:30
FSD Pharma Inc.   (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201...

at 02:30
Key Highlights TGA has granted provisional designation for new drug Lurbinectedin based on encouraging Phase 2 results and high unmet medical need A marketing application has now been accepted by the TGA under provisional evaluation pathway...

at 02:13
Isofol Medical AB (publ) ("Isofol" or the "Company") fully guaranteed new share issue with preferential rights for the Company's existing shareholders (the "Rights Issue"), which ended on June 1, 2020, was oversubscribed. Due to the strong demand...



News published on 8 may 2019 at 13:30 and distributed by: